Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam tosilate combined with esketamine for analgesia-sedation in mechanically ventilated ICU patients
ChiCTR2100053106Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Oct 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam, esketamine and sufentanil in None, sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Time to keep the target sedation. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
remimazolamesketaminesufentanil
Beyond the preview
Go deeper on ChiCTR2100053106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053106.